Literature DB >> 17599730

Resistance of rheumatoid arthritis patients to changing therapy: discordance between disease activity and patients' treatment choices.

Frederick Wolfe1, Kaleb Michaud.   

Abstract

OBJECTIVE: Despite advances in rheumatoid arthritis (RA) treatment, patients' decisions regarding therapy often deviate from expert recommendation. This study was undertaken to investigate patients' acceptance and satisfaction with therapy, willingness to change therapy, and reasons for not changing.
METHODS: Participants (n = 6,135) completed an 11-item questionnaire concerning treatment preferences. Eight questions assessed reasons for not wanting to change therapy. The contribution of individual predictors was determined by logistic regression analysis.
RESULTS: Questionnaire responses showed that 63.8% of the patients would not want to change therapy as long as their condition didn't get worse; 77.3% were satisfied with their medications, while 9.4% were dissatisfied. These assessments were weakly related to RA activity and functional status. Side effects had occurred in 22.4% of the patients during the previous 6 months, and in 65.5% at some period during their lifetime. Predictors of unwillingness to change therapy were satisfaction with RA control, which had an odds ratio (OR) of 6.8 (95% confidence interval [95% CI] 5.8-8.0), risk of side effects (OR 4.4 [95% CI 3.8-5.2]), physician opinion (OR 1.9 [95% CI 1.6-2.2]), fear of loss of control (OR 1.8 [95% CI 1.6-2.1]), lack of better medications (OR 1.4 [95% CI 1.2-1.6]), and costs (OR 1.3 [95% CI 1.1-1.6]). There was little difference in results between patients who were receiving biologic agents and those who were not.
CONCLUSION: There is substantial discrepancy between declared satisfaction with therapy and measured RA activity and functional status. Most RA patients are satisfied with their therapy, even many with abnormal scores. Fear of loss of control of RA and fear of side effects are major patient concerns. Maintenance of current status, rather than future improvement, appears to be a high priority for patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17599730     DOI: 10.1002/art.22719

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  51 in total

1.  Thresholds in disease activity for switching biologics in rheumatoid arthritis patients: experience from a large U.S. cohort.

Authors:  Jie Zhang; Ying Shan; George Reed; Joel Kremer; Jeffrey D Greenberg; Scott Baumgartner; Jeffrey R Curtis
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-12       Impact factor: 4.794

2.  Longitudinal Occurrence and Predictors of Patient-Provider Discordance Between Global Assessments of Disease Activity in Rheumatoid Arthritis: A Case-Control Study.

Authors:  Divya N V Challa; Zoran Kvrgic; Cynthia S Crowson; Eric L Matteson; Thomas G Mason; Clement J Michet; Daniel E Schaffer; Kerry A Wright; John M Davis
Journal:  Arthritis Care Res (Hoboken)       Date:  2019-12-10       Impact factor: 4.794

3.  Subjective numeracy and preference to stay with the status quo.

Authors:  Liana Fraenkel; Meaghan Cunningham; Ellen Peters
Journal:  Med Decis Making       Date:  2014-04-23       Impact factor: 2.583

Review 4.  Review: treat to target in rheumatoid arthritis: fact, fiction, or hypothesis?

Authors:  Daniel H Solomon; Asaf Bitton; Jeffrey N Katz; Helga Radner; Erika M Brown; Liana Fraenkel
Journal:  Arthritis Rheumatol       Date:  2014-04       Impact factor: 10.995

5.  Spontaneous mental associations with the words "side effect": Implications for informed and shared decision making.

Authors:  Sonya Izadi; Thorsten Pachur; Courtney Wheeler; Jaclyn McGuire; Erika A Waters
Journal:  Patient Educ Couns       Date:  2017-05-24

6.  Individual patient monitoring in daily clinical practice: a critical evaluation of minimal important change.

Authors:  Jos Hendrikx; Jaap Fransen; Wietske Kievit; Piet L C M van Riel
Journal:  Qual Life Res       Date:  2014-09-25       Impact factor: 4.147

7.  Timing and Impact of Decisions to Adjust Disease-Modifying Antirheumatic Drug Therapy for Rheumatoid Arthritis Patients With Active Disease.

Authors:  Yomei Shaw; Chung-Chou H Chang; Marc C Levesque; Julie M Donohue; Kaleb Michaud; Mark S Roberts
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-04-16       Impact factor: 4.794

8.  Drug-free holiday in patients with rheumatoid arthritis: a qualitative study to explore patients' opinion.

Authors:  I M Markusse; G Akdemir; T W J Huizinga; C F Allaart
Journal:  Clin Rheumatol       Date:  2014-01-28       Impact factor: 2.980

9.  Comparison of the expression profile of apoptosis-associated genes in rheumatoid arthritis and osteoarthritis.

Authors:  Huang Qingchun; Huang Runyue; Jie LiGang; Chu Yongliang; Wei Song; Zhao Shujing
Journal:  Rheumatol Int       Date:  2008-02-15       Impact factor: 2.631

10.  Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy.

Authors:  Jennifer L Barton
Journal:  Patient Prefer Adherence       Date:  2009-11-29       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.